ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) announced FDA approval and the launch of Pimozide Tablets 1 mg and 2 mg on April 20, 2026. The product is a generic of Orap and carries 180‑day competitive generic therapy (CGT) exclusivity. U.S. annual sales for pimozide total approximately $3.1 million based on February 2026 MAT IQVIA data.
The company said the launch brings a limited‑competition generic to market to serve customers and patients while the exclusive period restricts other generic entrants for 180 days.
Positive
- 180‑day CGT exclusivity for Pimozide Tablets
- Launch of generic Pimozide in 1 mg and 2 mg strengths
- Addressable U.S. market of approximately $3.1M annual sales
Negative
- Relatively small market size (~$3.1M annual sales) limits revenue upside
News Market Reaction – ANIP
In the Apr 20 session, ANIP gained 1.00%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Fda approval Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | FDA generic launch | Positive | -0.6% | FDA approval and launch of Isosorbide Mononitrate generic tablets. |
| Mar 14 | Label expansion | Positive | +1.7% | FDA approval expanding ILUVIEN label to include NIU-PS indication. |
| Mar 03 | New format approval | Positive | +1.1% | FDA approval for new prefilled syringe format of Cortrophin Gel. |
| Jan 02 | CGT generic launch | Positive | +0.3% | FDA approval and launch of Prucalopride Tablets with 180-day CGT exclusivity. |
| Oct 25 | Generic gel launch | Positive | -1.6% | FDA approval and launch of Estradiol Gel 0.06% as EstroGel generic. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
FDA approval headlines have produced mixed reactions, with an average move of +0.18% and both positive and negative next-day returns.
Over the past 18 months, ANI has repeatedly reported FDA approvals and launches across both branded and generic products, including ILUVIEN label expansion, Cortrophin Gel prefilled syringes, Prucalopride Tablets with 180-day CGT exclusivity, and Estradiol Gel 0.06%. Market reactions to these approvals have been modest, often within a few percentage points, and sometimes negative despite the positive regulatory outcomes. Today’s Pimozide launch with CGT exclusivity continues this strategy of targeting limited‑competition generic markets.
Key Terms
reference listed drug (rld) regulatory
cgt exclusivity regulatory
moving annual total (mat) technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap®.
"We are proud to announce the launch of Pimozide Tablets with 180-Day CGT exclusivity. We are excited to bring limited competition products to market and continue to provide generic alternatives to our customers and patients,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
U.S. annual sales for Pimozide Tablets total approximately
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s strategy; its plans with respect to the commercialization and potential sales of the Company’s products, including the launch of Pimozide Tablets; its efforts to bring limited-competition products to market and ensure that is high-quality products are readily accessible to its customers and patients in need; expansion plans for the Company’s Rare Disease, Generics and Brands businesses; and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates.
Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company’s approved products to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; delays and disruptions in the production of the Company’s approved products; delays or failure to obtain or maintain approvals by the FDA of the Company’s products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company’s products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of the Company’s manufacturing partners to meet its product demands and timelines; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; and general business and economic conditions, such as inflationary pressures and geopolitical conditions.
More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com
Source: ANI Pharmaceuticals, Inc.
